Antigen | Concomitant (Group A),^{a}N = 619 | Nonconcomitant (Group B),^{a}N = 618 | Estimated Percent Difference Group A – Group B^{b} (95% confidence interval) | ||
---|---|---|---|---|---|

m/n | Response (%) | m/n | Response (%) | ||

HPV6 | 501/501 | 100 | 514/514 | 100 | 0.0 (–0.8 to 0.7) |

HPV11 | 502/502 | 100 | 514/514 | 100 | 0.0 (–0.8 to 0.7) |

HPV16 | 513/513 | 100 | 530/530 | 100 | 0.0 (–0.7 to 0.7) |

HPV18 | 516/516 | 100 | 535/535 | 100 | 0.0 (–0.7 to 0.7) |

HPV31 | 514/514 | 100 | 536/536 | 100 | 0.0 (–0.7 to 0.7) |

HPV33 | 520/520 | 100 | 537/537 | 100 | 0.0 (–0.7 to 0.7) |

HPV45 | 523/523 | 100 | 539/539 | 100 | 0.0 (–0.7 to 0.7) |

HPV52 | 521/521 | 100 | 538/538 | 100 | 0.0 (–0.7 to 0.7) |

HPV58 | 519/519 | 100 | 537/537 | 100 | 0.0 (–0.7 to 0.7) |

*m*= number of subjects with the indicated response;*N*, number of subjects randomized to the respective vaccination group who received at least 1 injection;*n*, number of subjects contributing to the analysis. Seropositive is defined as anti-HPV serum levels (assessed by competitive Luminex immunoassay) greater or equal to 30, 16, 20, 24, 10, 8, 8, 8, 8 milliMerck units/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.↵

^{a}Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and MCV4 and Tdap on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as Group A and MCV4 and Tdap at month 1.↵

^{b}*P*value for noninferiority <.001 for all 9 antigens. The noninferiority criterion for seroconversion end points reported in this table was defined as statistically <5 percentage points decrease in Group A compared with Group B. Noninferiority of seroconversion rates in Group A relative to Group B was demonstrated if the lower limit of the 95% confidence interval for the percentage point difference was greater than –5.